In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance

Journal of Immunology

Volumn 184, Issue 6, 2010, Pages 2930-2938

  Buschow, Christian ^a   Charo, Jehad ^c   Anders, Kathleen ^c   Loddenkemper, Christoph ^a,b   Jukica, Ana ^c   Alsamah, Wisam ^c   Perez, Cynthia ^c   Willimsky, Gerald ^a,c   Blankenstein, Thomas ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Charité Campus Benjamin Franklin Medical Center   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; LUCIFERASE; LUCIFERIN; VIRUS LARGE T ANTIGEN; INTEGRASE; ONCOPROTEIN; VIRUS T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BIOLUMINESCENCE; CARCINOGENESIS; EFFECTOR CELL; EMBRYO; ENZYME ACTIVATION; FUSION GENE; GENE CASSETTE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; IMAGING; IN VIVO STUDY; LIVER CELL CARCINOMA; LOXP SITE; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIMIAN VIRUS 40; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; CELL TRANSFORMATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE COURSE; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LIVER TUMOR; LUMINESCENCE; MALE; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; PREDICTION AND FORECASTING; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; FEMALE; IMMUNE TOLERANCE; INTEGRASES; LIVER NEOPLASMS, EXPERIMENTAL; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; ONCOGENE PROTEINS, FUSION; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 77951927091     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900893     Document Type: Article

References (38)

1. Brinster, R. L., H. Y. Chen, A. Messing, T. van Dyke, A. J. Levine, and R. D. Palmiter. 1984. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 37: 367-379.
2. MacKay, K., L. J. Striker, C. A. Pinkert, R. L. Brinster, and G. E. Striker. 1987. Glomerulosclerosis and renal cysts in mice transgenic for the early region of SV40. Kidney Int. 32: 827-837.
3. Adams, T. E., S. Alpert, and D. Hanahan. 1987. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature 325: 223-228.
4. Knowles, B. B., J. McCarrick, N. Fox, D. Solter, and I. Damjanov. 1990. Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am. J. Pathol. 137: 259-262.
5. Bradl, M., A. Klein-Szanto, S. Porter, and B. Mintz. 1991. Malignant melanoma in transgenic mice. Proc. Natl. Acad. Sci. USA 88: 164-168.
6. Dubois, N., M. Bennoun, I. Allemand, T. Molina, G. Grimber, M. Daudet-Monsac, R. Abelanet, and P. Briand. 1991. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J. Hepatol. 13: 227-239.
7. Maroulakou, I. G., M. Anver, L. Garrett, and J. E. Green. 1994. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA 91: 11236-11240.
8. Gingrich, J. R., R. J. Barrios, R. A. Morton, B. F. Boyce, F. J. DeMayo, M. J. Finegold, R. Angelopoulou, J. M. Rosen, and N. M. Greenberg. 1996. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56: 4096-4102.
9. Furth, P. A. 1998. SV40 rodent tumour models as paradigms of human disease: transgenic mouse models. Dev. Biol. Stand. 94: 281-287.
10. Willimsky, G., and T. Blankenstein. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437: 141-146. (Pubitemid 41613441)
11. Ahuja, D., M. T. Sáenz-Robles, and J. M. Pipas. 2005. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24: 7729-7745. (Pubitemid 41670675)
12. Schell, T. D., L. M. Mylin, I. Georgoff, A. K. Teresky, A. J. Levine, and S. S. Tevethia. 1999. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J. Virol. 73: 5981-5993.
13. Otahal, P., T. D. Schell, S. C. Hutchinson, B. B. Knowles, and S. S. Tevethia. 2006. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J. Immunol. 177: 3089-3099.
14. Garbi, N., B. Arnold, S. Gordon, G. J. Hämmerling, and R. Ganss. 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172: 5861-5869.
15. Ye, X., J. McCarrick, L. Jewett, and B. B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91: 3916-3920.
16. Willimsky, G., M. Czéh, C. Loddenkemper, J. Gellermann, K. Schmidt, P. Wust, H. Stein, and T. Blankenstein. 2008. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 205: 1687-1700.
17. Contag, P. R., I. N. Olomu, D. K. Stevenson, and C. H. Contag. 1998. Bioluminescent indicators in living mammals. Nat. Med. 4: 245-247.
18. Gross, S., and D. Piwnica-Worms. 2005. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7: 5-15.
19. Edinger, M., Y. A. Cao, Y. S. Hornig, D. E. Jenkins, M. R. Verneris, M. H. Bachmann, R. S. Negrin, and C. H. Contag. 2002. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur. J. Cancer 38: 2128-2136.
20. Vooijs, M., J. Jonkers, S. Lyons, and A. Berns. 2002. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res. 62: 1862-1867.
21. Lyons, S. K., R. Meuwissen, P. Krimpenfort, and A. Berns. 2003. The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res. 63: 7042-7046.
22. Liao, C. P., C. Zhong, G. Saribekyan, J. Bading, R. Park, P. S. Conti, R. Moats, A. Berns, W. Shi, Z. Zhou, et al. 2007. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res. 67: 7525-7533.
23. Lyons, S. K., E. Lim, A. O. Clermont, J. Dusich, L. Zhu, K. D. Campbell, R. J. Coffee, D. S. Grass, J. Hunter, T. Purchio, and D. Jenkins. 2006. Non-invasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Res. 66: 4701-4707.
24. Vierboom, M. P., H. W. Nijman, R. Offringa, E. I. van der Voort, T. van Hall, L. van den Broek, G. J. Fleuren, P. Kenemans, W. M. Kast, and C. J. Melief. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186: 695-704.
25. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
26. Morgan, D. J., H. T. Kreuwel, and L. A. Sherman. 1999. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J. Immunol. 163: 723-727.
27. Overwijk, W. W., D. S. Lee, D. R. Surman, K. R. Irvine, C. E. Touloukian, C. C. Chan, M. W. Carroll, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1999. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA 96: 2982-2987.
28. Eck, S. C., and L. A. Turka. 2001. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity. Cancer Res. 61: 3077-3083.
29. Ludewig, B., A. F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R. M. Zinkernagel. 2000. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191: 795-804.
30. Li, L. P., P. M. Schlag, and T. Blankenstein. 1997. Transient expression of SV 40 large T antigen by Cre/LoxP-mediated site-specific deletion in primary human tumor cells. Hum. Gene Ther. 8: 1695-1700.
31. Kruschinski, A., A. Moosmann, I. Poschke, H. Norell, M. Chmielewski, B. Seliger, R. Kiessling, T. Blankenstein, H. Abken, and J. Charo. 2008. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. USA 105: 17481-17486.
32. Zheng, B., H. Vogel, L. A. Donehower, and A. Bradley. 2002. Visual genotyping of a coat color tagged p53 mutant mouse line. Cancer Biol. Ther. 1: 433-435.
33. Tatum, A. M., L. M. Mylin, S. J. Bender, M. A. Fischer, B. A. Vigliotti, M. J. Tevethia, S. S. Tevethia, and T. D. Schell. 2008. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J. Immunol. 181: 4406-4417.
34. von Boehmer, H. 1991. Positive and negative selection of the alpha beta T-cell repertoire in vivo. Curr. Opin. Immunol. 3: 210-215.
35. Kyewski, B., and R. Taubert. 2008. How promiscuity promotes tolerance: the case of myasthenia gravis. Ann. N. Y. Acad. Sci. 1132: 157-162.
36. Hino, O., T. Kitagawa, K. Nomura, K. Ohtake, L. Cui, Y. Furuta, and S. Aizawa. 1991. Hepatocarcinogenesis in transgenic mice carrying albumin-promoted SV40 T antigen gene. Jpn. J. Cancer Res. 82: 1226-1233.
37. Spiotto, M. T., and H. Schreiber. 2006. Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen- regulated Cre-loxP recombination. J. Immunol. Methods 312: 201-208.
38. Novellino, L., C. Castelli, and G. Parmiani. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54: 187-207.